Aquestive Therapeutics (AQST) reported $11.87 million in revenue for the quarter ended December 2024, representing a year-over-year decline of 10.2%. EPS of -$0.19 for the same period compares to -$0.12 a year ago.
The reported revenue represents a surprise of -12.11% over the Zacks Consensus Estimate of $13.5 million. With the consensus EPS estimate being -$0.14, the EPS surprise was -35.71%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Aquestive Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Manufacture and supply revenue: $10.66 million compared to the $11.38 million average estimate based on four analysts. The reported number represents a change of -3% year over year.
- Revenues- License and royalty revenue: $0.83 million versus the four-analyst average estimate of $1.86 million. The reported number represents a year-over-year change of -55.6%.
- Revenues- Co-development and research fees: $0.27 million compared to the $0.43 million average estimate based on three analysts. The reported number represents a change of -18.2% year over year.
- Revenue - Proprietary product sales, net: $0.10 million compared to the $0.20 million average estimate based on two analysts.
Shares of Aquestive Therapeutics have returned -11.1% over the past month versus the Zacks S&P 500 composite's -4.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks Names #1 Semiconductor Stock
It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>Aquestive Therapeutics, Inc. (AQST) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
